Market Overview

Nordion to Sell Targeted Therapies Business to BTG plc fro $200M in Cash


Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and
services for the prevention, diagnosis and treatment of disease,
announced that it has entered into an agreement to divest its Targeted
Therapies business to BTG plc (LSE: BTG) (“BTG”), an international
specialist healthcare company based in London, United Kingdom, for a
cash purchase price of US$200 million. Net of cash taxes and transaction
costs, Nordion expects to realize approximately US$185 million on
closing. The transaction is anticipated to be completed by the end of
June 2013.

Nordion manufactures and commercializes TheraSphere®, a targeted liver
cancer therapy, the sole product in its Targeted Therapies business.
Under the terms of the transaction agreements, BTG is expected

See full press release

Posted-In: News Guidance Global


Related Articles (NDZ)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Benzinga Market Primer: Thursday May 23

Amazon Kindle Fire HD, Kindle Fire HD 8.9" to Ship Beginning June 13 to 170 Countries